Pierre-Alain Ruffieux, CEO of Lonza, will leave the Basel-based company at the end of September.
According to the Swiss Contract Development and Manufacturing Organization (CDMO), the separation is by mutual agreement.
The Lonza Board of Directors also announced that Albert M. Baehny, Chairman of the Board, will assume the additional responsibility as CEO ad interim until a permanent successor is appointed.
Baehny had already led the Group on an interim basis in 2020 after then-CEO Marc Funk left the Swiss chemical and biotech group in January 2020 after less than a year in office.
Ruffieux has been CEO since November 2020 and was previously Head of Global Pharma Technical Operations at Roche.
The medium-term strategy and outlook will be discussed in detail at the Capital Markets Day in Visp on October 17, 2023. At the end of July, Lonza reported sales of CHF 3.1 billion and sales growth of 3.2% (5.6% on a constant currency basis) for the first half of 2023, representing underlying sales growth of approximately 10%. CHF 922 million core EBITDA resulted in a margin of 30%.
Source: chemanager-online.com
As the clock ticks down on 2024, Novo Holdings’ proposed $16.5 billion buyout of CDMO giant Catalent—which the companies have said they expect to close before year-end—just received a major vote of confidence from antitrust officials overseas.
With EuroAPI’s restructuring plan underway, the Sanofi spinoff has pulled a new CEO from within its ranks to guide the company’s next chapter. Drug ingredients specialist EuroAPI on Monday said it had accepted the resignations of Ludwig de Mot as CEO and Viviane Monges as chair of the manufacturer’s board.
During an investor update Thursday, Lonza unveiled its “One Lonza” restructuring strategy, under which the company will reorganize its CDMO business, reshape its operating model, work to “elevate” manufacturing and engineering and expand its production footprint.
